ADMA Biologics (NASDAQ:ADMA) Shares Gap Down - Here's What Happened

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s share price gapped down prior to trading on Tuesday . The stock had previously closed at $15.83, but opened at $14.90. ADMA Biologics shares last traded at $14.43, with a volume of 1,239,191 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have commented on ADMA shares. Raymond James raised their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday.

ADMA Biologics Stock Down 4.4 %

The stock has a market cap of $4.00 billion, a price-to-earnings ratio of 60.39 and a beta of 0.75. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a 50 day simple moving average of $16.67 and a 200 day simple moving average of $17.96.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Hollencrest Capital Management purchased a new position in shares of ADMA Biologics during the third quarter valued at approximately $30,000. Larson Financial Group LLC purchased a new position in shares of ADMA Biologics during the third quarter valued at approximately $31,000. National Bank of Canada FI purchased a new position in shares of ADMA Biologics during the third quarter valued at approximately $35,000. GAMMA Investing LLC boosted its position in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after buying an additional 967 shares during the last quarter. Finally, Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics during the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.